BIO-key Reports Strong Q1 Revenue Growth, Reduced Loss, and Projects H1 Profitability
BKYI sits 27% above its 52-week low of $3.1 on light trading volume (0.2× avg).
Summary
BIO-key reported strong Q1 2026 financial results, including a 34% revenue increase and a reduced net loss, while projecting profitability for the first half of 2026.
Key Events · Earnings and Guidance · BKYI
-
Strong Q1 2026 Revenue Growth
Revenues increased 34% year-over-year to $2.15 million, and 74% compared to Q4 2025, driven by expanded license renewals and hardware sales.
-
Significant Bottom-Line Improvement
Net loss substantially improved to $(165K) in Q1 2026, compared to $(737K) in Q1 2025 and $(1.722M) in Q4 2025, reflecting strong gross margins and cost management.
-
Positive H1 2026 Profitability Outlook
The company expects Q2 revenues to rise 65% to approximately $2.8 million and projects overall profitability for the first half of 2026, a significant turnaround from a $(1.9M) net loss in H1 2025.
-
Context of Nasdaq Suspension
These strong operational results are announced shortly after the company's common stock was suspended from Nasdaq and moved to OTC Markets, with management actively working to regain compliance.
Analysis · BKYI · Technology
BIO-key International announced significantly improved first-quarter 2026 financial results, with a 34% increase in revenue and a substantial reduction in net loss. The company also provided strong guidance, projecting a 65% revenue increase for Q2 and overall profitability for the first half of 2026. These positive operational results are critical as the company works to regain Nasdaq compliance following its recent suspension.
At the time of this filing, BKYI was trading at $3.94 on OTC in the Technology sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.